PharmaPoint: Healthcare-Associated Gram-Negative Infections – Global Drug Forecast and Market Analysis to 2026

Invite Credit Card Holder to pay

Requester Details

Credit Card Holder Details

Company Details

Message to be included

Healthcare-associated infections (HAIs) are a major threat to patient safety, and place a substantial economic burden on healthcare systems. HAIs occur in hospitalized patients, and are not present at the time of admission. Acute care hospitals are the primary settings for contracting HAIs, with a high concentration occurring within non-nursery wards and intensive care units (ICUs).The most common types of HAIs are related to the use of invasive devices or surgical procedures, and fall into the following infection site categories: catheter-associated urinary tract infection (CAUTI), central line-associated bloodstream infection (CLABSI), hospital-associated pneumonia/ventilator-associated pneumonia (HAP/VAP), and surgical site infection (SSI).

The pharmaceutical industry’s battle against Gram-negative bacteria requires ongoing development and novel, innovative approaches for the development of new antibiotics as well as non-antibiotic based approaches. Due to the lack of novel scaffolds being developed over the last few decades and limited investments into antibiotic R&D during this century, the prevalence of resistant Gram-negative bacteria, especially in the hospital setting, has increased significantly; antibiotic resistance is now considered a major threat to the life expectancy of current future generations, including in developed countries. Consequently, industry and governments have recently ramped up their involvement in this space, and several promising antibiotics are now in the late-stage development.

Scope

Overview of HAIs caused by Gram-negative bacteria, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

Topline market revenue from 2016–2026 for HAIs caused by Gram-negative bacteria. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.

Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting therapeutics sales in the 7MM.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.

Analysis of the current and future market competition in the global therapeutics market for HAIs caused by Gram-negative bacteria. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global therapeutics market for HAIs caused by Gram-negative bacteria.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the therapeutics market for HAIs caused by Gram-negative bacteria in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Companies mentioned

Merck & Co

Pfizer

The Medicines Company

Shionogi & Co Ltd

Tetraphase Pharmaceuticals Inc

MerLion Pharmaceuticals Pte Ltd

Achaogen

Aridis Pharmaceuticals

MedImmune LLC

Allergan

Merck & Co

Pfizer

The Medicines Company

Shionogi & Co Ltd

Tetraphase Pharmaceuticals Inc

MerLion Pharmaceuticals Pte Ltd

Achaogen

Aridis Pharmaceuticals

MedImmune LLC

Allergan

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Executive Summary

2.1 Launch of Patented ...

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Executive Summary

2.1 Launch of Patented Antibiotics Will Drive Solid Growth Over the Forecast Period

2.2 Pipeline Portfolios Target Highly Resistant Bacteria in Strong Collaborations With Governments

2.3 Drug Portfolios Address Some Unmet Needs, but Some Opportunities Remain With New Foreseeable Challenges

2.4 Companies Must Quickly Adapt to Exploit Opportunities in an Evolving Marketplace

2.5 Novel Antibiotics Are Poised to Drive Growth Despite Entering a Highly Genericized Marketplace

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Infection Scope and Coverage Overview

4.2 Etiology and Pathophysiology

4.2.1 Etiology

4.2.2 Pathophysiology

4.3 Symptoms

4.4 Prognosis

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.3.1 US

5.3.2 5EU

5.3.3 Japan

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for Suspected HAIs and Gram-Negative HAIs (2016–2026)

5.5.1 Suspected Incident Cases of Select HAIs

5.5.2 Diagnosed Incident Cases of Select Gram-Negative HAIs

5.5.3 Suspected Incident Cases of Select HAIs by Infection Site

5.5.4 Diagnosed Incident Cases of Select Gram-Negative HAIs by Infection Site

5.5.5 Diagnosed Incident Cases of Select Gram-Negative HAIs by Causative Agent

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.1.1 Diagnosis

6.1.2 Treatment Guidelines

6.1.3 Clinical Practice

6.1.4 Antibiotic Stewardship Programs

6.1.5 Off-Label Use of Antibiotics

6.2 US

6.3 5EU

6.4 Japan

7 Competitive Assessment

7.1 Overview

7.2 Product Profiles – Beta-Lactam Antibiotics

7.2.1 Overview

7.2.2 Fixed Dose Beta-Lactam Combination Drugs

7.2.3 Monobactam antibiotics

7.2.4 Carbapenems

7.2.5 Cephalosporins

7.3 Product Profiles – Fluoroquinolones

7.3.1 Overview

7.3.2 Levofloxacin (numerous brand names)

7.3.3 Ciprofloxacin (numerous brand names)

7.3.4 Moxifloxacin (numerous brand names)

7.4 Product Profiles – Polymixins

7.4.1 Overview

7.4.2 Forecast

7.5 Product Profiles – Aminoglycosides

7.5.1 Overview

7.5.2 Amikacin (numerous brand names)

7.5.3 Gentamicin (numerous brand names)

7.5.4 Tobramycin (numerous brand names)

7.6 Product Profiles – Tetracyclines

7.6.1 Tygacil (tigecycline)

7.7 Product Profiles – Other Antibiotics

8 Unmet Needs Assessment and Opportunity Analysis

8.1 Overview

8.2 Novel Approaches in Drug Development to Address Antibiotic Resistance

8.2.1 Unmet Need

8.2.2 Gap Analysis

8.2.3 Opportunity

8.3 Novel Broad-Spectrum Antibiotics

8.3.1 Unmet Need

8.3.2 Gap Analysis

8.3.3 Opportunity

8.4 Antibiotics Positioned as Pathogen- and Resistance-Specific Therapies

8.4.1 Unmet Need

8.4.2 Gap Analysis

8.4.3 Opportunity

8.5 Expansion of Antimicrobial Stewardship Programs and Awareness

8.5.1 Unmet Need

8.5.2 Gap Analysis

8.5.3 Opportunity

8.6 Financial Incentives for Drug Development and Collaborative Efforts Between Governments/Non-Profits/For-Profits

8.6.1 Unmet Need

8.6.2 Gap Analysis

8.6.3 Opportunity

8.7 Improved Diagnostics for Pathogens and Resistance Patterns

8.7.1 Unmet Need

8.7.2 Gap Analysis

8.7.3 Opportunity

8.8 Improving the Safety and Administration Profile of Antibiotics

8.8.1 Unmet Need

8.8.2 Gap Analysis

8.8.3 Opportunity

8.9 Improved Clinical Trial Design

8.9.1 Unmet Need

8.9.2 Gap Analysis

8.9.3 Opportunity

8.10 Improved Prevention of Healthcare-Associated Infections

8.10.1 Unmet Need

8.10.2 Gap Analysis

8.10.3 Opportunity

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.2.1 Antibiotics

9.2.2 Antibodies

9.3 Other Drugs in Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Company Profiles – Current Players

10.3.1 Pfizer

10.3.2 Merck& Co.

10.3.3 The Medicines Company

10.3.4 Shionogi & Co., Ltd.

10.3.5 Tetraphase Pharmaceuticals Inc.

10.3.6 MerLion Pharmaceuticals Pte., Ltd.

10.3.7 Achaogen

10.3.8 Aridis Pharmaceuticals

10.3.9 MedImmune LLC

10.3.10 Allergan

10.4 Other Companies With Early-Stage Products

10.4.1 Roche/Genentech

10.4.2 Wockhardt Ltd.

10.4.3 Allecra

10.4.4 Zavante

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Suspected Infections and Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Antibiotic Resistance Patterns

12.3.5 Drugs Included in Each Therapeutic Class

12.3.6 Launch and Patent Expiry Dates

12.3.7 General Pricing Assumptions

12.3.8 Individual Drug Assumptions

12.3.9 Generic Erosion

12.3.10 Pricing of Pipeline Agents

12.4 Primary Research – Key Opinion Leaders Interviewed for This Report

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Reviewers

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

List of tables

Table 1: Healthcare-Associated Infections by Gram-Negative Bacteria: Key Metrics in the Seven Major Pharmaceutical Markets

Table 2: Characteristics of Most Important Gram-Negative Bacteria

Table 3 ...

Table 1: Healthcare-Associated Infections by Gram-Negative Bacteria: Key Metrics in the Seven Major Pharmaceutical Markets

Table 2: Characteristics of Most Important Gram-Negative Bacteria

Table 3: Prevalence of Antibiotic Resistance in Gram-Negative Bacteria Throughout the 7MM

Table 4: Symptoms of HAIs Caused by Gram-Negative Bacteria

Table 5: Risk Factors for Diagnosed Incident Cases of HAIs

Table 6: 7MM, Suspected Incident Cases of Select HAIs, Ages ≥18 Years, Both Sexes, N, Select Years 2016–2026

Table 7: 7MM, Diagnosed Incident Cases of Select Gram-Negative HAIs, Ages ≥18 Years, Both Sexes, N, Select Years 2016–2026

Table 8: National and International Treatment Guidelines for HAIs

Table 9: HAI Disease Management, Country Profile – US

Table 10: HAI Disease Management, Region Profile – 5EU

Table 11: HAI Disease Management, Region Profile – Japan

Table 12: Common Susceptibility Patterns in Gram-Negative Bacteria Isolated From the General Hospital Setting (non-ICU) and ICUs

Table 13: Leading Branded Treatments for HAI, 2016

Table 14: SWOT Analysis of Main Antibiotic Classes for HAIs Caused by Gram-Negative Bacteria

Table 15: Product Profile – Avycaz

Table 16: Efficacy of Avycaz in Patients with cIAIs

Table 17: Efficacy of Avycaz in Patients with cUTIs

Table 18: Safety of Avycaz

Table 19: Product Profile – Zerbaxa

Table 20: Efficacy of Zerbaxa in Patients with cIAIs

Table 21: Efficacy of Zerbaxa in Patients with cUTIs

Table 22: Safety of Zerbaxa

Table 23: Product Profile – Piperacillin/tazobactam

Table 24: Efficacy of Piperacillin/tazobactam in Patients with cIAIs

Table 25: Efficacy of Piperacillin/tazobactam in Patients with HAP

Table 26: Efficacy of Piperacillin/tazobactam in Patients with cUTIs

Table 27: Safety of Piperacillin/Tazobactam

Table 28: Product Profile – Ticarcillin/clavulanate

Table 29: Efficacy of Ticarcillin/clavulanate in Patients with cIAIs1

Table 30: Product Profile – Aztreonam

Table 31: Efficacy of Aztreonam

Table 32: Safety of Aztreonam in Patients with Bacterial Infections

Table 33: Product Profile – Doribax

Table 34: Efficacy of Doribax in Patients with cIAIs

Table 35: Efficacy of Doribax in Patients with cUTIs

Table 36: Safety of Doribax

Table 37: Product Profile – Invanz

Table 38: Efficacy of Invanz in Patients with cIAIs

Table 39: Efficacy of Invanz in Patients with cUTIs

Table 40: Safety of Invanz

Table 41: Most Frequently Used Cephalosporins in HAIs

Table 42: Product Profile – Levofloxacin

Table 43: Efficacy of Levaquin in Patients with Nosocomial Pneumonia

Table 44: Efficacy of Levaquin in Patients with cUTIs and Acute Pyelonephritis

Table 45: Safety of Levofloxacin in Patients with Bacterial Infections

Table 46: Product Profile – Ciprofloxacin

Table 47: Efficacy of Ciprofloxacin in Patients with cUTIs

Table 48: Safety of Ciprofloxacin in Patients with Bacterial Infections

Table 49: Product Profile – Moxifloxacin

Table 50: Efficacy of Moxifloxacin in Patients with cIAIs

Table 51: Safety of Moxifloxacin in Patients with Bacterial Infections

Table 52: Aminoglycoside Susceptibility of Strains Isolated from Hospitalized Patients with Pneumonia*

Table 53: Product Profile – Amikacin

Table 54: Efficacy of Amikacin in Patients with Bacterial Infections

Table 55: Safety of Amikacin in Patients with Bacterial Infections

Table 56: Product Profile – Gentamicin

Table 57: Efficacy of Gentamicin in Patients with Bacterial Infections

Table 58: Safety of Gentamicin in Patients with Bacterial Infections

Table 59: Product Profile – Tobramycin

Table 60: Product Profile – Tygacil

Table 61: Efficacy of Tygacil in Patients with cIAIs

Table 62: Efficacy of Tygacil in Patients with HAP/VAP

Table 63: Safety of Tygacil

Table64: Infrequently Used Antibiotics for the Treatment of HAI Caused by Gram-Negative Bacteria

Table 65: Key Late-Stage Pipeline Agents for HAIs Caused by Gram-Negative Bacteria, 2017

Table 66: Product Profile – Avibactam/Aztreonam

Table 67: Pathogen Susceptibility to Avibactam/Aztreonam

Table 68: Avibactam/Aztreonam SWOT Analysis, 2017

Table 69: Product Profile – Meropenem/Vaborbactam

Table 70: Meropenem/Vaborbactam – Phase III Clinical Trials

Table 71: Meropenem/Vaborbactam SWOT Analysis, 2017

Table 72: Product Profile – Relebactam/Imipenem/Cilastin

Table 73: Relebactam/Imipenem/Cilastin – Phase II and Phase III Clinical Trials

Table 74: Relebactam/Imipenem/Cilastin – Phase II Results (cIAI/cUTI)

Table 75: Safety of Relebactam/Imipenem/Cilastin

Table 76: Relebactam/Imipenem/Cilastin SWOT Analysis, 2017

Table 77: Product Profile – Cefiderocol

Table 78: Cefiderocol – Phase II and Phase III Clinical Trials

Table 79: Cefiderocol SWOT Analysis, 2017

Table 80: Product Profile – Eravacycline

Table 81: Eravacycline – Phase II and Phase III Clinical Trials

Table 82: Eravacycline – Phase III Clinical Trials Results for cIAIs

Table 83: Eravacycline – Safety Profile

Table 84: Eravacycline SWOT Analysis, 2017

Table 85: Product Profile – Finafloxacin

Table 86: Finafloxacin – Phase II Efficacy for Patients with UTI

Table 87: Finafloxacin SWOT Analysis, 2017

Table 88: Product Profile – Plazomicin

Table 89: Plazomicin – Clinical Trials

Table 90: Plazomicin – Results from Phase III Trial with cUTI Patients

Table 91: Plazomicin – Results from Phase III Trial with cUTI Patients

Table 92: Plazomicin – Safety Results from Phase III Trials

Table 93: Eravacycline SWOT Analysis, 2017

Table 94: Product Profile – Panobacumab

Table 95: Aerumab – Phase II Clinical Trials

Table 96: Aerumab – Phase II Clinical Trial Results

Table 97: Aerumab SWOT Analysis, 2017

Table 98: Product Profile – MEDI3902

Table 99: MEDI3902 – Phase II Clinical Trials

Table 100: MEDI3902 – Safety Data

Table 101: MEDI3902 SWOT Analysis, 2017

Table 102: Drugs in Development for HAI Caused by Gram-Negative Bacteria, 2017

Table 103: Key Companies in the HAIs Marketplace in the 7MM, 2017

Table 104: Pfizer’s HAI Portfolio Assessment, 2017

Table 105: Merck& Co’s Gram-Negative HAIs Portfolio Assessment, 2017

Table 106: The Medicines Company’s Gram-Negative HAIs Portfolio Assessment, 2017

Table 107: Shionogi’s Gram-Negative HAIs Portfolio Assessment, 2017

Table 108: Tetraphase Pharmaceutical’s Gram-Negative HAIs Portfolio Assessment, 2017

Table 109: MerLion Pharmaceutical’s Gram-Negative HAIs Portfolio Assessment, 2017

Table 110: Achaogen’s Gram-Negative HAIs Portfolio Assessment, 2017

Table 111: Aridis’ HAI Portfolio Assessment, 2017

Table 112: MedImmune’s Gram-Negative HAI Portfolio Assessment, 2017

Table 113: Allergan’s Gram-Negative HAI Portfolio Assessment, 2017

Table 114: Global (7MM) Sales Forecasts ($M) for Therapeutics Against HAIs Caused by Gram-Negative Bacteria, 2016–2026

Table 115: HAIs Caused by Gram-Negative Bacteria – Global Drivers and Barriers, 2016–2026

Table 116: Sales Forecasts ($M) for Therapeutics Against HAIs Caused by Gram-Negative Bacteria in the US, 2016–2026

Table 117: Key Events Impacting Sales for HAIs Caused by Gram-Negative Bacteria in the US, 2016–2026

Table 118: HAIs caused by Gram-Negative Bacteria – US Drivers and Barriers, 2016–2026

Table 119: 5EU Sales Forecasts ($M) for Therapeutics Against HAIs Caused by Gram-Negative Bacteria, 2016–2026

Table 120: Key Events Impacting Sales for HAIs Caused by Gram-Negative Bacteria in the 5EU, 2016–2026

Table 121: HAIs Caused by Gram-Negative Bacteria – 5EU Drivers and Barriers, 2016–2026

Table 122: Sales Forecasts ($M) for Therapeutics Against HAIs Caused by Gram-Negative Bacteria in Japan, 2016–2026

Table 123: Key Events Impacting Sales for HAIs Caused by Gram-Negative Bacteria in Japan, 2016–2026

Table 124: HAIs Caused by Gram-Negative Bacteria – Japan Drivers and Barriers, 2016–2026

Table 125: Key Historical and Projected Launch Dates for HAI Caused by Gram-negative Bacteria Across the 7MM

Table 126: Projected Patent Expiry Dates for HAI Caused by Gram-negative Bacteria Across the 7MM

Table 127: Key Assumptions for Avycaz

Table 128: Key Assumptions for Zerbaxa

Table 129: Key Assumptions for Piperacillin/tazobactam

Table 130: Key Assumptions for Ticarcillin/tazobactam

Table 131: Key Assumptions for Aztreonam

Table 132: Key Assumptions for Doribax

Table 133: Key Assumptions for Invanz

Table 134: Key Assumptions for Meropenem

Table 135: Key Assumptions for Imipenem

Table 136: Key Assumptions for Cefoxitin

Table 137: Key Assumptions for Cefotaxime

Table 138: Key Assumptions for Ceftriaxone

Table 139: Key Assumptions for Cefoperazone

Table 140: Key Assumptions for Ceftazidime

Table 141: Key Assumptions for Cefepime

Table 142: Key Assumptions for Zevtera

Table 143: Key Assumptions for Levofloxacin

Table 144: Key Assumptions for Ciprofloxacin

Table 145: Key Assumptions for Moxifloxacin

Table 146: Key Assumptions for Amikacin

Table 147: Key Assumptions for Gentamicin

Table 148: Key Assumptions for Tobramycin

Table 149: Key Assumptions for Polymyxin B

Table 150: Key Assumptions for Polymyxin E

Table 151: Key Assumptions for Tygacil

Table 152: Key Assumptions for Other Antibiotics

Table 153: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

List of figures

Figure 1: Global Sales for HAI Caused by Gram-Negative Bacteria by Region, 2016 and 2026

Figure 2: Company Portfolio Gap Analysis for HAIs against Gram-Negative ...

Figure 1: Global Sales for HAI Caused by Gram-Negative Bacteria by Region, 2016 and 2026

Figure 2: Company Portfolio Gap Analysis for HAIs against Gram-Negative Bacteria, 2016–2026

Figure 3: Competitive Assessment of the Late-Stage Pipeline for HAIs against Gram-Negative Bacteria

Figure 4: Illustration Depicting the Key Structural Properties of Gram-Negative Bacteria

Figure 5: Sites of Relevant Gram-Negative HAI Sites

Figure 6: Illustration Depicting the Key Mechanisms of Antibiotic Resistance Observed in Gram-Negative Bacteria

Figure 7: Sources Used to Forecast Suspected Incident Cases of HAIs and Suspected Incident Cases of HAIs by Infection Site

Figure 8: Sources Used and Not Used to Forecast Diagnosed Incident Cases of Gram-Negative HAIs and Diagnosed Incident Cases of Gram-Negative HAIs by Infection Site

Figure 9: Sources Used and Not Used to Forecast Diagnosed Incident Cases of Gram-Negative HAIs by Infection Site by Causative Agent

Figure 10: 7MM, Suspected Incident Cases of Select HAIs by Infection Site, Both Sexes, Ages ≥18 Years, 2016

Figure 11: 7MM, Diagnosed Incident Cases of Select Gram-Negative HAIs by Infection Site, Both Sexes, Ages ≥18 Years, 2016

Figure 12: 7MM, Diagnosed Incident Cases of Gram-Negative CAUTI by Causative Agent, Both Sexes, Ages ≥18 Years, 2016

Figure 13: 7MM, Diagnosed Incident Cases of Gram-Negative CLABSI by Causative Agent, Both Sexes, Ages ≥18 Years, 2016

Figure 14: 7MM, Diagnosed Incident Cases of Gram-Negative HAP/VAP by Causative Agent, Both Sexes, Ages ≥18 Years, 2016

Figure 15: 7MM, Diagnosed Incident Cases of Gram-Negative SSI by Causative Agent, Both Sexes, Ages ≥18 Years, 2016

Figure 16: Empirical and Targeted Treatments of HAIs

Figure 17: Overview of the Unmet Needs for HAIs Caused by Gram-Negative Bacteria.

Figure 18: Overview of the Development Pipeline for HAI Against Gram-Negative Bacteria

Figure 19: HAIs Caused by Gram-Negative Bacteria – Phase II‒III Pipeline, 2017

Figure 20: Competitive Assessment of Late-Stage Pipeline Agents in HAIs Caused by Gram-Negative Bacteria, 2016–2026

Figure 21: Clinical and Commercial Positioning of Aztreonam/Avibactam

Figure 22: Clinical and Commercial Positioning of Meropenem/Vaborbactam

Figure 23: Clinical and Commercial Positioning of Relebactam/Imipenem/Cilastin

Figure 24: Clinical and Commercial Positioning of Cefiderocol

Figure 25: Clinical and Commercial Positioning of Eravacycline

Figure 26: Clinical and Commercial Positioning of Finafloxacin

Figure 27: Clinical and Commercial Positioning of Plazomicin

Figure 28: Clinical and Commercial Positioning of Aerumab

Figure 29: Clinical and Commercial Positioning of MEDI3902

Figure 30: Company Portfolio Gap Analysis in Gram-Negative HAIs, 2016–2026

Figure 31: Global Sales for Therapeutics Against HAIs Caused by Gram-Negative Bacteria, by Country/Region, 2016 and 2026

Figure 32: Global Sales for Therapeutics Against HAIs Caused by Gram-Negative Bacteria, by Drug Class, 2016 and 2026

Figure 33: Sales for Therapeutics Against HAIs Caused by Gram-Negative Bacteria in the US, by Drug Class, 2016 and 2026

Figure 34: Sales for Therapeutics Against HAIs Caused by Gram-Negative Bacteria in the 5EU by Drug Class, 2016 and 2026

Figure 35: Sales for Therapeutics Against HAIs Caused by Gram-Negative Bacteria in Japan, by Drug Class, 2016 and 2026

Figure 36: Patient Flow Used for HAIs with Gram-Negative Bacteria

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Saved reports